{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:22:34Z","timestamp":1787030554178,"version":"build-2736575974"},"reference-count":36,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.1943","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T04:39:17Z","timestamp":1739335157000},"source":"Crossref","is-referenced-by-count":4,"title":["MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib\u2011resistant chronic myeloid leukemia cells"],"prefix":"10.3892","volume":"22","author":[{"given":"Akihiro","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kindai University, Higashi\u2011Osaka, Osaka 577\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Tsubaki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, Kagawa 769\u20112193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Obana","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kindai University, Higashi\u2011Osaka, Osaka 577\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taira","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, Kagawa 769\u20112193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Komori","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Sanuki, Kagawa 769\u20112193, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kindai University, Higashi\u2011Osaka, Osaka 577\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kindai University, Higashi\u2011Osaka, Osaka 577\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kindai University, Higashi\u2011Osaka, Osaka 577\u20118502, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"232","key":"key20250314123421_b1-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.3390\/genes15020232","article-title":"Frequencies of BCR::ABL1 transcripts in patients with chronic myeloid leukemia: A meta-analysis","volume":"15","author":"Romero-Morelos","year":"2024","journal-title":"Genes (Basel)"},{"key":"key20250314123421_b2-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/ijbs.86305","article-title":"Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"20","author":"Sun","year":"2024","journal-title":"Int J Biol Sci"},{"key":"key20250314123421_b3-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11899-023-00703-w","article-title":"Real-world management of CML: Outcomes and treatment patterns","volume":"18","author":"Held","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"key20250314123421_b4-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"issue":"155161","key":"key20250314123421_b5-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155161","article-title":"The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia","volume":"254","author":"El-Tanani","year":"2024","journal-title":"Pathol Res Pract"},{"key":"key20250314123421_b6-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cncr.33933","article-title":"The cure of leukemia through the optimist's prism","volume":"128","author":"Kantarjian","year":"2022","journal-title":"Cancer"},{"key":"key20250314123421_b7-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"3300","key":"key20250314123421_b8-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143300","article-title":"Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia","volume":"14","author":"Poudel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"e13420","key":"key20250314123421_b9-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13420","article-title":"Activation of ERK1\/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells","volume":"56","author":"Tsubaki","year":"2023","journal-title":"Cell Prolif"},{"key":"key20250314123421_b10-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"38717","DOI":"10.18632\/oncotarget.16314","article-title":"Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells","volume":"8","author":"Tsubaki","year":"2017","journal-title":"Oncotarget"},{"key":"key20250314123421_b11-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41571-023-00842-2","article-title":"Pharmacological reactivation of p53 in the era of precision anticancer medicine","volume":"21","author":"Tuval","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"651","key":"key20250314123421_b12-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44771-9","article-title":"Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease","volume":"15","author":"Scott","year":"2024","journal-title":"Nat Commun"},{"key":"key20250314123421_b13-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s1535-6108(03)00020-5","article-title":"BCR\/ABL activates mdm2 mRNA translation via the La antigen","volume":"3","author":"Trotta","year":"2003","journal-title":"Cancer Cell"},{"key":"key20250314123421_b14-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"30487","DOI":"10.18632\/oncotarget.5890","article-title":"Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells","volume":"6","author":"Carter","year":"2015","journal-title":"Oncotarget"},{"key":"key20250314123421_b15-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.18632\/oncotarget.13951","article-title":"The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR\/ABL and T315I mutant BCR\/ABL through promoting proteosomal degradation of BCR\/ABL proteins","volume":"8","author":"You","year":"2017","journal-title":"Oncotarget"},{"issue":"1866","key":"key20250314123421_b16-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121866","article-title":"Overactivation of Akt contributes to MEK inhibitor primary and acquired resistance in colorectal cancer cells","volume":"11","author":"Tsubaki","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20250314123421_b17-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41374-018-0114-8","article-title":"Overexpression of HIF-1\u03b1 contributes to melphalan resistance in multiple myeloma cells by activation of ERK1\/2, Akt, and NF-\u03baB","volume":"99","author":"Tsubaki","year":"2019","journal-title":"Lab Invest"},{"issue":"173957","key":"key20250314123421_b18-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173957","article-title":"Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation","volume":"898","author":"Morii","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"key20250314123421_b19-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"key20250314123421_b20-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1179\/1607845413Y.0000000094","article-title":"Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib","volume":"19","author":"Silveira","year":"2014","journal-title":"Hematology"},{"issue":"mjac074","key":"key20250314123421_b21-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjac074","article-title":"The ARTS of p53-dependent mitochondrial apoptosis","volume":"14","author":"Hao","year":"2023","journal-title":"J Mol Cell Biol"},{"key":"key20250314123421_b22-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/cbin.11600","article-title":"P53 long noncoding RNA regulatory network in cancer development","volume":"45","author":"Aravindhan","year":"2021","journal-title":"Cell Biol Int"},{"key":"key20250314123421_b23-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/mc.22061","article-title":"MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib","volume":"53","author":"Liu","year":"2014","journal-title":"Mol Carcinog"},{"key":"key20250314123421_b24-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20250314123421_b25-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3892\/ijmm.2017.3205","article-title":"Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib","volume":"41","author":"Cheng","year":"2018","journal-title":"Int J Mol Med"},{"issue":"e83510","key":"key20250314123421_b26-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2","volume":"8","author":"Ding","year":"2013","journal-title":"PLoS One"},{"key":"key20250314123421_b27-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/leu.2011.7","article-title":"p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells","volume":"25","author":"Peterson","year":"2011","journal-title":"Leukemia"},{"issue":"101521","key":"key20250314123421_b28-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101521","article-title":"Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia","volume":"5","author":"Adnan Awad","year":"2024","journal-title":"Cell Rep Med"},{"issue":"13","key":"key20250314123421_b29-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6010013","article-title":"p53 gene (NY-CO-13) levels in patients with chronic myeloid leukemia: The role of imatinib and nilotinib","volume":"6","author":"Al-Kuraishy","year":"2018","journal-title":"Diseases"},{"key":"key20250314123421_b30-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.7754\/Clin.Lab.2017.170413","article-title":"The relationship between MDM2 T309G polymorphism and leukemia in the Chinese population: Evidence from a meta-analysis","volume":"63","author":"Zhao","year":"2017","journal-title":"Clin Lab"},{"issue":"7","key":"key20250314123421_b31-BR-22-4-01943","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Front Oncol"},{"key":"key20250314123421_b32-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/0145-2126(93)90161-d","article-title":"Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line","volume":"17","author":"Law","year":"1993","journal-title":"Leuk Res"},{"key":"key20250314123421_b33-BR-22-4-01943","first-page":"81","article-title":"Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562\/TPA cells","volume":"22","author":"Usuda","year":"2003","journal-title":"Int J Oncol"},{"key":"key20250314123421_b34-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: An exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20250314123421_b35-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1158\/0008-5472.CAN-11-0058","article-title":"Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a","volume":"71","author":"Brennan","year":"2011","journal-title":"Cancer Res"},{"key":"key20250314123421_b36-BR-22-4-01943","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5483\/BMBRep.2022-0095","article-title":"Hypoxia-inducible factor 1\u03b1 inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells","volume":"56","author":"Tsubaki","year":"2023","journal-title":"BMB Rep"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T06:34:32Z","timestamp":1741934072000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.1943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,12]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.1943","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"65"}}